Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

RSV Treatment Market Will Surpass $2.3 Billion by 2024

By GlobalData | January 13, 2016

(Photo credit: William Brawley)

The global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9%, says research and consulting firm GlobalData.

According to the company’s latest report*, this robust growth, which will occur across the seven Major Markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by multiple new product launches in the currently sparse RSV arena.

Christopher J. Pace, Ph.D., GlobalData’s Director of Infectious Diseases, states that Synagis (palivizumab) is the only licensed product indicated for the prevention of RSV in infants at a high risk of severe infection, and there are no prophylactic agents approved for adults.

Pace explains: “Despite Synagis being effective in many patients, its short half-life and prohibitively high cost limit its utility.

“However, the anticipated launches of novel prophylactic monoclonal antibodies (mAbs) led by MedImmune’s MEDI8897 and Regeneron’s REGN2222, have provided hope for more cost-effective alternatives to Synagis. GlobalData expects these pipeline agents will be important players in the RSV space across the 7MM by 2024.”

In addition, the anticipated licensure of the first adult vaccine to offer protection against RSV, Novavax’s RSV-F Vaccine, will also stimulate rapid growth in a previously untapped segment of the RSV marketplace, with elderly patients, especially those living in nursing homes, driving the uptake of this vaccine.

Pace continues: “These new products come at a time when RSV presents a growing socioeconomic and public health burden. New game-changing agents will be enthusiastically welcomed, particularly as healthcare stakeholders are becoming increasingly open to novel interventions that may provide indirect cost-savings by shortening, or even outright preventing, hospital stays.

“Despite the RSV treatment market’s promising prospects, there will be formidable logistical and financial hurdles to overcome in order to successfully assimilate novel RSV vaccines into existing immunization program infrastructure. However, such barriers will not hinder exciting market growth to 2024.”

*OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024

Lead image source.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE